Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BBSRC is investing £10m in 20 advanced scientific research instruments.

BBSRC is investing £10m in 20 advanced scientific research instruments under the Advanced Life Sciences Research Technology initiative (ALERT 13) to help keep the UK at the forefront of biological sciences research. Shankar Srinivas and Paul Riley from the Department of Physiology, Anatomy and Genetics, together with Ilan Davis (Biochemistry and Micron Oxford Advanced Bioimaging Unit), Jordan Raff (Sir William Dunn School of Pathology) and Roger Patient (Weatherall Institute of Molecular Medicine) have been awarded one of the UK’s first two commercial Fluorescence Light Sheet Microscopes to probe cell and tissue dynamics, worth just under £500k. This instrument will allow groups from Oxford and further afield to examine dynamic process within living cells in exquisite detail, enabling exciting advances in a broad range of areas in cell, developmental and stem cell biology.

Read more

Similar stories

PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19

Coronavirus COVID-19 General Research

In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.